See more : Garrett Motion Inc. (GTX) Income Statement Analysis – Financial Results
Complete financial analysis of bioAffinity Technologies, Inc. (BIAF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of bioAffinity Technologies, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Ester Industries Limited (ESTER.BO) Income Statement Analysis – Financial Results
- Day One Biopharmaceuticals, Inc. (DAWN) Income Statement Analysis – Financial Results
- Lancashire Holdings Limited (LCSHF) Income Statement Analysis – Financial Results
- Oncopeptides AB (publ) (ONPPF) Income Statement Analysis – Financial Results
- Envea Société Anonyme (ALTEV.PA) Income Statement Analysis – Financial Results
bioAffinity Technologies, Inc. (BIAF)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.bioaffinitytech.com
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.53M | 4.80K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.74M | 467.00 | 4.82K | 22.24K | 40.28K |
| Gross Profit | 791.62K | 4.34K | -4.82K | -22.24K | -40.28K |
| Gross Profit Ratio | 31.26% | 90.28% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.72M | 1.29M | 1.33M | 1.61M | 1.85M |
| General & Administrative | 0.00 | 2.73M | 880.77K | 994.34K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.79M | 2.73M | 880.77K | 994.34K | 1.20M |
| Other Expenses | 249.59K | -1.87M | 724.93K | -4.28M | 0.00 |
| Operating Expenses | 8.76M | 4.02M | 2.21M | 2.60M | 3.05M |
| Cost & Expenses | 10.51M | 4.02M | 2.21M | 2.60M | 3.09M |
| Interest Income | 122.13K | 46.71K | 424.00 | 1.07K | 2.78K |
| Interest Expense | 37.13K | 2.53M | 1.00M | 382.17K | 214.83K |
| Depreciation & Amortization | 249.59K | 10.18K | 4.82K | 22.24K | 40.28K |
| EBITDA | -7.63M | -5.61M | -2.20M | -6.86M | -3.05M |
| EBITDA Ratio | -301.26% | -121,196.96% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.97M | -4.01M | -2.21M | -2.60M | -3.09M |
| Operating Income Ratio | -314.84% | -83,511.51% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 57.21K | -4.14M | -4.12M | -4.66M | -212.06K |
| Income Before Tax | -7.92M | -8.15M | -6.32M | -7.27M | -3.30M |
| Income Before Tax Ratio | -312.58% | -169,720.05% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 20.99K | 2.46K | 1.95K | 2.75K | 3.20K |
| Net Income | -7.94M | -8.15M | -6.33M | -7.27M | -3.31M |
| Net Income Ratio | -313.41% | -169,771.25% | 0.00% | 0.00% | 0.00% |
| EPS | -0.91 | -1.81 | -0.86 | -0.99 | -0.45 |
| EPS Diluted | -0.91 | -1.81 | -0.86 | -0.99 | -0.45 |
| Weighted Avg Shares Out | 8.75M | 4.50M | 7.38M | 7.38M | 7.38M |
| Weighted Avg Shares Out (Dil) | 8.75M | 4.50M | 7.38M | 7.38M | 7.38M |
What Is Going on With bioAffinity (BIAF) Stock Today?
bioAffinity (BIAF) Stock Pops 100% in Red-Hot IPO
Source: https://incomestatements.info
Category: Stock Reports